Compare DexCom, Inc. (DXCM) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Micron Technology, Inc. — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Micron Technology, Inc. trades at $1,029 (market cap $1.17T). The key difference: Micron Technology, Inc. is far larger — about 36.7× DexCom, Inc.'s market cap, and Micron Technology, Inc. pays a 0.06% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Micron Technology, Inc. for 48 Days on average.
| DXCM | MU | |
|---|---|---|
Market Cap | $31.86B | $1.17T |
Volume | 3,607,070 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $92.34 | $1.21K |
52-Week Low | $54.84 | $181.60 |
Typical Hold Time | 62 Days | 48 Days |
Enterprise Value | $31.32B | $1.13T |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Micron Technology (MU) trades at $1,029, down 5.42% over the past session, despite strong fundamental performance. The stock shows bullish technical signals with robust earnings beats in recent quarters (Q2 2026 EPS of $33.42 vs. $31.77 expected) and exceptional profitability metrics, including a 63.8% net income margin. Recent news highlights multi-year growth driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030.
Outlook remains positive with analyst consensus strongly bullish (82.85% buy ratings) and a $1,590 price target, though risks include cyclical memory pricing and potential AI demand normalization. The company's strong cash flow generation ($17.53B operating cash flow in 2025) and expanding margins support continued upside potential for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
